The expression characteristic and prognostic role of Siglec‐15 in lung adenocarcinoma [PDF]
The Clinical Respiratory JournalSialic acid‐binding immunoglobulin‐like lectin‐15 (Siglec‐15) has been identified as an immune suppressor and a promising candidate for immunotherapy of cancer management.
Haijun Sun +7 more
doaj +3 more sources
Prognostic significance of tumoral Siglec-15 expression in solid tumors: a systematic review and meta-analysis [PDF]
Frontiers in ImmunologyBackgroundSiglec-15 has emerged as a novel immune checkpoint molecule and a potential therapeutic target in solid tumors. Previous studies reported inconsistent prognostic significance of tumoral Siglec-15 expression across cancer types.
Ningning Zhang +4 more
doaj +3 more sources
Siglec-15 as a potential molecule involved in osteoclast differentiation and bone metabolism [PDF]
HeliyonSialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is a well-conserved type I transmembrane protein of the Siglecs family, distributed in macrophages and dendritic cells in the human spleen and lymph nodes.
Jiaqi Lu +5 more
doaj +3 more sources
Bioinformatic analysis reveals prognostic value and immunotherapy potential of Siglec-15 in laryngeal squamous cell carcinoma [PDF]
HeliyonBackground: Laryngeal squamous cell carcinoma (LSCC) is the ultimate common malignant head and neck cancer with dismal prognosis. The expression pattern and clinical significance of Siglec-15 (Sialic acid-binding immunoglobulin-like lectin 15) in LSCC ...
Xiaoting Chen +4 more
doaj +3 more sources
Siglec-15 antibody–GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages [PDF]
Journal for ImmunoTherapy of CancerBackground Sialic acid-binding immunoglobulin-like lectin (Siglec)-15-expressing tumor-associated macrophages (TAMs) drive immunosuppression in the tumor microenvironment (TME), promoting CD8+ T cell exhaustion and limiting immunotherapy efficacy.
Jun Li +12 more
doaj +3 more sources
Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer [PDF]
Frontiers in OncologyIntroductionSialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is a novel immune checkpoint, similar to programmed death-ligand (PD-L1), and has emerged as a potential target for cancer immunotherapy. Until recently, little was known about the
Chengbiao Chu +4 more
doaj +4 more sources
Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer [PDF]
BMC CancerThe sialic acid binding Ig like lectin 15 (Siglec-15) was previously identified as tumor immune suppressor gene in some human cancers with elusive molecular mechanism to be elucidated.
Xingzhi Li +6 more
doaj +3 more sources
Immuno-PET Imaging of Siglec-15 Using the Zirconium-89-Labeled Therapeutic Antibody, NC318
Molecular Imaging, 2023 Objective. Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is overexpressed in various cancers which has led to the development of therapeutic anti-Siglec-15 monoconal antibodies (mAbs).
Elaine M. Jagoda +12 more
doaj +2 more sources
Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes [PDF]
Frontiers in Immunology, 2023 Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as Siglec-15. Presently, small molecule inhibitors targeting Siglec-15 are
Mohammed Saqif Ahmad +5 more
doaj +2 more sources
OncoImmunology, 2020 Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is considered a novel anti-tumor target comparable to programmed cell death 1 ligand 1(PD-L1). However, little is known about Siglec-15.
Baihui Li +8 more
doaj +2 more sources